Adjuvant Trastuzumab: Do We Finally Know How Long is Not Too Long?

Venkatraman Radhakrishnan¹

¹Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India

Address for correspondence Venkatraman Radhakrishnan, MD, DM, Department of Medical and Pediatric Oncology, Cancer Institute (WIA), Adyar, Chennai 600020, Tamil Nadu, India (e-mail: venkymd@gmail.com).

Ind J Med Paediatr Oncol 2021;42:293–296.

Anti–human epidermal growth factor receptor 2 (anti-HER2)-targeted treatment is the standard of care for treating HER2-positive breast cancer in the adjuvant, neoadjuvant, and metastatic setting. Trastuzumab was the first anti-HER2 therapy introduced and is the most widely used anti-HER2 drug.

Adjuvant trastuzumab has shown improvement in disease-free survival (DFS) and overall survival (OS) in HER2-positive breast cancer in multiple trials.¹-⁴ These trials had given adjuvant trastuzumab for 1 year, and therefore 1 year has been the standard duration of prescribing trastuzumab.

Trials have examined giving adjuvant trastuzumab over a shorter duration (6 months, 3 months, or 9 weeks) instead of the standard 1-year duration.⁵-¹⁰ Shorter duration trastuzumab is attractive because of the reduced duration of treatment, decreased cardiac toxicity, and lesser financial toxicity.

However, randomized trials examining shorter duration of trastuzumab have given contradictory results and therefore the jury is still open on the duration of adjuvant trastuzumab. Gulia et al have tried to address this ambiguity through their recently published meta-analysis.¹¹ What is unique about their paper is that they were able to extract individual patient data (IPD) from the Kaplan–Meier curves for the various adjuvant trastuzumab trials, using specialized software called the WebPlotDigitizer. The WebPlotDigitizer is a validated and reliable software for data extraction.¹² An IPD meta-analysis is more robust than a trial-level meta-analysis. The meta-analysis included only randomized controlled trials (RCTs) that compared the shorter duration of trastuzumab (<1 year) with 1 year of trastuzumab.

All trials comparing the shorter duration of adjuvant trastuzumab with 1-year trastuzumab must be noninferior in nature as the regulatory approval trials compared 1-year adjuvant trastuzumab to placebo. It will be difficult to show a superiority of a shorter duration of adjuvant trastuzumab to 1-year trastuzumab.¹³ Five randomized trials comparing the shorter duration of adjuvant trastuzumab were noninferior to 1-year trastuzumab.¹-³ We also need to show that a shorter duration of adjuvant trastuzumab is not only noninferior but associated with lesser toxicity, lower mortality, and better quality of life compared with 1-year trastuzumab. There is no clear consensus on fixing the acceptable margin for noninferiority in an RCT.¹⁴ The studies included in the meta-analysis by Gulia et al had a noninferiority margin for the hazard ratio (HR) ranging from 1.15 to 1.53.¹¹ Gulia et al took the median noninferiority margin for all the trials included in their meta-analysis and this was an HR of 1.3.¹¹ That is if the upper limit of the 95% confidence interval (CI) of the HR for DFS and OS for the shorter duration of trastuzumab was less than 1.3, then they could conclude that the shorter duration of trastuzumab was noninferior to 1-year trastuzumab. This would mean that a 30% reduced DFS or OS with shorter trastuzumab was acceptable. That is, patients have a 30% increased probability of disease relapse or death if they received a shorter duration of adjuvant trastuzumab compared with the standard 1-year adjuvant trastuzumab. Many patients and clinicians might not be willing to accept this increased risk. I would opine that for curable cancer in the adjuvant setting the noninferiority margin should be kept as low as possible. A noninferiority margin of 1.15 to 1.2 would have been appropriate for this meta-analysis. If the authors had chosen this noninferiority margin, then their meta-analysis would not have concluded that a shorter duration of adjuvant trastuzumab is not inferior to 1-year adjuvant trastuzumab.

PHARE and PERSEPHONE were trials that evaluated 6 months versus 1 year of adjuvant trastuzumab.⁹,¹⁰ These trials were similar in design and outcomes, except that PHARE had a noninferiority limit for HR for DFS of 1.15 and PERSEPHONE had a limit of 1.25. The trials had similar HR and 95% CI (PHARE, HR: 1.08, 95% CI: 0.93–1.25; PERSEPHONE, HR: 1.07, 95% CI: 0.93–1.24). However, PHARE was a negative trial and
PERSEPHONE was a positive trial just because of the noninferiority margin they chose. The other trial comparing 6-month versus 1-year trastuzumab was the HORG trial and this trial took a noninferiority margin of 1.57 for DFS and it failed to show noninferiority. 8

The HR for DFS for the five trials included in the IPD meta-analysis by Gulia et al was 1.14 (95% CI: 1.03–1.25) and this was like the upper limit of CI reported by PHARE and PERSEPHONE.9,11 The absolute difference for 5-year DFS between the shorter duration and 1-year trastuzumab was 1.7% (85.4% vs. 87.1%) and for OS was 1.1% (92.3% vs. 94.4%) and this was not statistically significant.11 This means approximately 58 patients would need to be treated with 1-year trastuzumab to prevent 1 relapse and 90 patients would be needed to be treated with 1-year trastuzumab to prevent one death. Assuming a price of Indian Rupees 20,000 for a 440-mg vial of generic trastuzumab and one vial is used every 3 weeks (including the loading dose), the approximate cost of preventing one relapse would be Rs. 19,720,000 and for preventing one death would be Rs. 30,600,000 with 1-year adjuvant trastuzumab. The high cost required to see the minimal benefits of 1-year trastuzumab might act as a deterrent for its use in the public health system funded by the taxpayer’s money. The same might also apply to most of the patients who pay out of pocket and cannot afford the cost of treatment.

World Health Organization (WHO) defines an intervention to be cost effective if it costs less than three times the average per capita income per disability-adjusted life year (DALY) or quality-adjusted life-year (QALY).14 Therefore a formal cost-effectiveness analysis is required to see if 1-year adjuvant trastuzumab meets the WHO threshold of cost effectiveness. A recent study from India compared the cost effectiveness of 1 year, 6 months, and 9 weeks of adjuvant trastuzumab in breast cancer.15 The authors calculated the incremental cost per QALY gained with the use of adjuvant trastuzumab. The study concluded that 1-year trastuzumab is not cost effective in India at the current price. The 6-month and 9-week schedules were cost-effective with the most benefit seen with the 9 weeks schedule. A price reduction of 15 to 35% increased the probability of 1-year trastuzumab use being cost effective to 90%.

Gulia et al made an interesting observation in their results.11 When analyzed using a superiority design, 1-year trastuzumab was associated with a significantly better DFS (HR: 0.87; 95% CI: 0.80–0.96) and OS (HR: 0.86; 95% CI: 0.75–0.97). Instead of 1-year adjuvant trastuzumab had the initial regulatory trials compared 6 months adjuvant trastuzumab to placebo, there would have been a possibility that future trials comparing 1 year versus 6 months of trastuzumab could have shown superiority of 1-year trastuzumab. This assumption is based on the results of the meta-analysis conducted by Gulia et al.11 In such a situation a shorter duration of adjuvant trastuzumab (<1 year) might not be considered an appropriate treatment. Two-year adjuvant trastuzumab was compared with 1 year, and this was not shown to be superior.16

When dissecting trials that used adjuvant trastuzumab for 6 months (three trials) versus those that used adjuvant trastuzumab for 9 to 12 weeks (three trials), it was observed that trials that used 9 to 12 weeks of trastuzumab failed to show noninferiority for DFS and OS compared with 1-year trastuzumab. The HRs for DFS and OS (9–12-week vs. 1-year trastuzumab) were 1.27 (95% CI: 1.07–1.51) and 1.25 (95% CI: 0.96–1.63), respectively. The HRs for DFS and OS (6-month vs. 1-year trastuzumab) were 1.10 (95% CI: 0.99–1.23) and 1.14 (95% CI: 0.90–1.32), respectively. Therefore, noninferiority could only be demonstrated for DFS and not OS for 6-month versus 1-year adjuvant trastuzumab. These results suggest that 9 to 12 weeks of trastuzumab is inadequate and 6 months of adjuvant trastuzumab cannot replace 1-year trastuzumab if OS is our endpoint. I would opine that we should not lump all short-duration trastuzumab in one group, it might not be like comparing apples and oranges, but it is like comparing different breeds of apples. Overall, taken together all short-duration regimens (6 months, 12 weeks, and 9 weeks), results show noninferiority. However, when considered individually, only the 6-month regimen showed noninferiority and not the 12 weeks or 9 weeks regimens.

The meta-analysis showed a 3% reduction in symptomatic congestive heart failure with a shorter duration of trastuzumab versus 1-year trastuzumab (3.9 vs. 6.9%, p < 0.001).11 Asymptomatic left ventricular ejection fraction decline was lower in the shorter trastuzumab group compared with the 1-year trastuzumab (5 vs. 7%, p = 0.049). These findings indicate that a shorter duration of trastuzumab is associated with lesser cardiac toxicities compared with 1-year trastuzumab. However, cardiac toxicity per se should not be a factor for deciding the duration of adjuvant trastuzumab as cardiac toxicity is mostly reversible. The pros and cons of a longer duration of trastuzumab vis-à-vis cardiac toxicity should be discussed with the patient. The patient can then make an informed decision whether they prefer 1-year trastuzumab due to better DFS and OS or shorter duration of trastuzumab due to the increased risk of cardiac toxicity with 1-year adjuvant trastuzumab. The treatment of early breast cancer has evolved from the time of recruitment of these trials. Today’s emphasis is on nonanthracycline-based adjuvant regimens, especially in low-risk, node-negative, estrogen receptor (ER)-positive patients which probably negates the additional cardiotoxicity seen with 12 months of trastuzumab when combined with anthracycline-based regimens of the trial eras.17 We need more trials of adjuvant trastuzumab with nonanthracycline-based regimens to see the effectiveness of a shorter duration of trastuzumab.18

Individually five out of six trials failed to prove noninferiority of shorter duration of trastuzumab against 1-year trastuzumab. However, overall, the meta-analysis was able to show noninferiority for DFS and OS albeit with a 25% possibility of inferiority at upper CI.11 The authors have discussed the strengths and limitations of their meta-analysis in detail in their paper.11 I would echo their concerns in that the trials included in their meta-analysis are heterogeneous with regard to the time of randomization, chemotherapy drugs, and scheduled used, and follow-up period. Therefore, even
if we agree that a shorter duration of trastuzumab is enough we do not know the ideal chemotherapy backbone for it. However, the majority of the neoadjuvant and adjuvant trastuzumab trials have used docetaxel at a dose of 100 mg/m² q 3 weekly as a combination chemotherapy backbone.17

The authors could not show a benefit of shorter duration of trastuzumab in a subgroup analysis of patient age (< or >50 years), ER status, axillary nodal status, stage, and timing of trastuzumab (sequential or concurrent with chemotherapy).11 However, the authors concluded that 1-year trastuzumab is superior to shorter duration trastuzumab in patients who are older than 50 years, are ER-negative, and receive concomitant trastuzumab as the lower limit of 95% CI did not cross unity. These subgroups analyses were not preplanned in the individual trials and therefore their results should be taken as hypothesis generating and not practice changing. We also need a longer follow-up in the ER-positive subgroup to assess the benefit of adjuvant trastuzumab as relapses in this subgroup can occur late.18 Surprisingly heavy nodal positivity did not influence the outcome. One reason for this could be that the authors defined pathologically staged N3 axillary lymph node as ≥4 nodes instead of the American Joint Committee on Cancer (AJCC) staging that defines N3 as ≥10 nodes.

Adjuvant anti-HER2 therapy itself has evolved over the trial periods with additions of newer molecules like pertuzumab (APHINITY trial) and the concept of dual HER2 blockade in the adjuvant setting and extended HER2 blockade with neratinib after 1 year of adjuvant trastuzumab (ExteNET trial).19,20 Therefore, the question of 6 versus 12 months of a single anti HER2 agent is probably losing its relevance.

A similar meta-analysis was published by Chen et al in 2019 with the same patient cohort.21 However, they demonstrated that 1-year adjuvant trastuzumab was superior to a shorter duration of adjuvant trastuzumab. Both DFS (HR: 1.13; 95% CI: 1.03–1.25; p = 0.01) and OS (HR: 1.16; 95% CI: 1.01–1.32; p = 0.03) were significantly improved with conventional 1-year trastuzumab treatment compared with shorter treatments. This is opposite to the observation of Gulia et al.11 All it indicates that meta-analysis of pooled data done retrospectively may vary as per the way the observer wants to see it. Chen et al did not do an IPD meta-analysis, unlike Gulia et al.11,21

The million-rupee question is do we change our practice when we go to our clinics on Monday morning based on the results of the meta-analysis of Gulia et al.11 The answer is both yes and no. Yes, 6-month adjuvant trastuzumab is noninferior to 1-year adjuvant trastuzumab for DFS. Yes, that the financial toxicity of a shorter regimen is lesser, and in a resource-limited setting the incremental benefits seen with a longer duration of trastuzumab does not justify the cost. No, we do not know which subgroup of patients will benefit from shorter or 1-year trastuzumab. No, a 9- to 12-week trastuzumab schedule cannot replace a 6-month schedule. However, due to financial constraints if only giving 9- to 12-week trastuzumab is possible then this is better than giving no trastuzumab as has been reported from studies in India.22-24 The patients should be explained the pros and cons of 1-year and shorter trastuzumab and their views also need to be considered when recommending the treatment.

Based on subgroup analysis, the short course trastuzumab of 6 months has some role in low-risk early breast cancer patients with ER-positive, node-negative, and small tumor size and will be beneficial from a cost-effectiveness point, especially in low- and middle-income countries (LMICs) like India. Such a strategy may encourage more and more patients from LMICs to take trastuzumab and get benefited from it in an adjuvant setting.

Patients with tumor size less than 3 cm and with node-negative HER2-positive disease planned for chemotherapy with single-agent weekly paclitaxel for 12 cycles should receive adjuvant trastuzumab for 1-year as per the Adjuvant Paclitaxel Trastuzumab (APT) trial design.25

Unless we are clear what is truly acceptable as a noninferiority margin, we might never come to a consensus whether shorter duration trastuzumab is enough, till then we should continue to use our clinical judgment based on the resources we have and the patient’s disease burden.

**Funding**

None.

**Conflict of Interest**

None declared.

**References**


